ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
Inhibition of CD154:CD11b interactions using a novel nanotherapeutic improves allograft survival.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The CD40-CD154 axis in transplantation: from immunobiology to therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
It is now appreciated that CD154 and CD40 may be differentially effective as therapeutic targets in transplantation owing to the ability of CD154 to bind to a second receptor, CD11b. We previously reported that the combination of anti-CD40 and a specific CD154:CD11b blocker enhanced allograft survival compared to anti-CD40 alone. In the current study, we have utilized a novel nanoparticle-based approach to more effectively deliver CD154:CD11b blockade during transplantation. Recipients of allogeneic skin grafts were treated with either CTLA-4Ig (CD80/ CD86 blocker) or the combination of CTLA-4Ig plus a hyaluronic acid nanoparticle-conjugated CD154:CD11b peptide inhibitor (iPepHANP). Results indicated that iPepHANP synergized with CTLA-4Ig in prolonging allograft survival and inhibiting donor-reactive CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.